Last reviewed 2026-04-20 · How we verify

androgen deprivation therapy

At a glance

Approved indications

No approved indications tracked.

Common side effects

• Fatigue
• Hypertension
• Arthralgia
• Constipation
• Back pain
• Nausea
• Pain in extremity
• Hot flush
• Diarrhoea
• Headache
• Hot flashes
• Oedema peripheral

Key clinical trials

• A Single-Arm Phase II Study of Neoadjuvant Intensified Androgen Deprivation (Leuprolide and Abiraterone Acetate) in Combination With AKT Inhibition (Capivasertib) for High-Risk Localized Prostate Cancer With PTEN Loss (PHASE2)
• A Phase I/II Study of PDS01ADC With Docetaxel and Abiraterone in Adults With Metastatic Castration Sensitive and PDS01ADC With Docetaxel in Castration Resistant Prostate Cancer (PHASE1, PHASE2)
• Androgen Suppression Combined With Nodal Irradiation and Dose Escalated Prostate Treatment (PHASE3)
• High-Risk prostatE Cancer radiatiOn Versus surgERy
• An Open-label Study Comparing Lutetium (177Lu) Vipivotide Tetraxetan Versus Observation in PSMA Positive OMPC. (PHASE3)
• PRO-BOOST-N: Prostate-First Versus Combined Prostate and Nodal Dose Escalation in PSMA PET-Staged Node-Positive Prostate Cancer (PHASE2, PHASE3)
• SUPERvised Three-month Exercise Program in MEN With Prostate cAncer Receiving Androgen-deprivaTioN thERapy (NA)
• Mechanisms, Predictors, and Social Determinants of Cardiotoxicity in Prostate Cancer

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

• androgen deprivation therapy CI brief — competitive landscape report
• androgen deprivation therapy updates RSS · CI watch RSS
• Jonsson Comprehensive Cancer Center portfolio CI